ArticleFrontiers in oncology2022

Cost-effectiveness analysis of nivolumab combination therapy in the first-line treatment for advanced esophageal squamous-cell carcinoma.

Shixian Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.